JP6946304B2 - 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 - Google Patents

増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 Download PDF

Info

Publication number
JP6946304B2
JP6946304B2 JP2018532639A JP2018532639A JP6946304B2 JP 6946304 B2 JP6946304 B2 JP 6946304B2 JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018532639 A JP2018532639 A JP 2018532639A JP 6946304 B2 JP6946304 B2 JP 6946304B2
Authority
JP
Japan
Prior art keywords
gdf15
seq
liver
protein
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018532639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538335A5 (enExample
JP2018538335A (ja
Inventor
チャトコー，ウィリアム
リチャード ネヴィル ハドコック，ジョン
リチャード ネヴィル ハドコック，ジョン
アレックス ヘルドウェイン，カート
アレックス ヘルドウェイン，カート
リチャードソン ウセラ，アイミー
リチャードソン ウセラ，アイミー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6946304(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2018538335A publication Critical patent/JP2018538335A/ja
Publication of JP2018538335A5 publication Critical patent/JP2018538335A5/ja
Application granted granted Critical
Publication of JP6946304B2 publication Critical patent/JP6946304B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2018532639A 2015-12-22 2016-12-20 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 Expired - Fee Related JP6946304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270967P 2015-12-22 2015-12-22
US62/270,967 2015-12-22
PCT/IB2016/057839 WO2017109706A1 (en) 2015-12-22 2016-12-20 Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)

Publications (3)

Publication Number Publication Date
JP2018538335A JP2018538335A (ja) 2018-12-27
JP2018538335A5 JP2018538335A5 (enExample) 2020-01-30
JP6946304B2 true JP6946304B2 (ja) 2021-10-06

Family

ID=57796765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532639A Expired - Fee Related JP6946304B2 (ja) 2015-12-22 2016-12-20 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法

Country Status (5)

Country Link
US (2) US20190000923A1 (enExample)
EP (1) EP3393494A1 (enExample)
JP (1) JP6946304B2 (enExample)
CN (1) CN108367053A (enExample)
WO (1) WO2017109706A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MY192917A (en) 2014-07-30 2022-09-15 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
US20190248852A1 (en) 2016-05-24 2019-08-15 Novo Nordisk A/S MIC-1 Compounds and Use Thereof
CN110087666B (zh) * 2016-11-13 2024-04-30 想象制药公司 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019048660A1 (en) 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
BR112020020823A2 (pt) 2018-04-09 2021-01-19 Amgen Inc. Proteínas de fusão do fator de diferenciação do crescimento 15
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
WO2020031149A2 (en) 2018-08-10 2020-02-13 Novartis Ag Gfral extracellular domains and methods of use
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
JOP20210111A1 (ar) * 2018-11-20 2023-01-30 Janssen Pharmaceutica Nv نظائر عامل gdf15 وطرق استخدامه في تقليل وزن الجسم و/أو تخفيض امتصاص الطعام
WO2020152367A1 (en) 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
KR20200124176A (ko) * 2019-04-23 2020-11-02 주식회사 엘지화학 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4085077A4 (en) * 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
TW202140525A (zh) * 2020-01-08 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 Ｆｇｆ２１突變體蛋白及其融合蛋白
CN111333505B (zh) * 2020-03-31 2022-07-26 东莞市东阳光生物药研发有限公司 制备长链脂肪二酸单苄酯的方法及其应用
CN115244076B (zh) * 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
KR102569644B1 (ko) * 2020-10-30 2023-08-23 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CN118076373A (zh) * 2021-05-21 2024-05-24 株式会社柳韩洋行 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
AU2022278933A1 (en) 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
CN118995820A (zh) * 2024-10-22 2024-11-22 江苏凯基生物技术股份有限公司 一种生长分化因子-15及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
CA2225377C (en) 1995-06-22 2013-08-13 St. Vincent's Hospital Sydney Limited Novel tgf-.beta. like cytokine
AU4725697A (en) * 1996-11-01 1998-05-29 Shionogi & Co., Ltd. Model mouse for human diseases
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1638963E (pt) 2003-05-20 2009-11-18 Novartis Ag Heterociclos de azoto n-acilado como ligandos de receptores activados pelo proliferador peroxissomal
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
WO2009135778A1 (en) * 2008-05-06 2009-11-12 F. Hoffmann-La Roche Ag Animal model for diabetes
US8785151B2 (en) 2008-10-24 2014-07-22 Bernhard Geierstanger Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
DK2670847T3 (en) * 2011-02-03 2017-01-16 Xoma Technology Ltd Methods and Materials for Improving Functional Protein Expression in Bacteria
CN103533951B (zh) * 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
AU2012308491B2 (en) * 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
MX2014009129A (es) * 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
WO2015196145A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
EP3851445A1 (en) 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
US20170334971A1 (en) 2014-12-22 2017-11-23 Novo Nordisk A/S Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof

Also Published As

Publication number Publication date
US20220249614A1 (en) 2022-08-11
JP2018538335A (ja) 2018-12-27
US20190000923A1 (en) 2019-01-03
EP3393494A1 (en) 2018-10-31
WO2017109706A1 (en) 2017-06-29
CN108367053A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
JP6946304B2 (ja) 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US11111285B2 (en) Glucagon-GLP-1-GIP triple agonist compounds
US20200181216A1 (en) Hsa-gdf-15 fusion polypeptide and use thereof
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
JP6490011B2 (ja) 肥満を治療するためのグルカゴン／ｇｌｐ−１アゴニスト
CN102131516B (zh) 包含弹性蛋白样肽的治疗剂
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
TW202140065A (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
CN113728013B (zh) Glp-1和fgf21的融合蛋白的缀合物
WO2021239082A1 (zh) Glp-1和gip受体双重激动剂化合物及其应用
CN102918055A (zh) 新的胰高血糖素类似物
JP2009508505A (ja) ペプチダーゼに対する耐性が向上しているｇｌｐ−１（グルカゴン様ペプチド−１）融合ペプチド
KR20160079875A (ko) Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
WO2013148871A1 (en) Engineered polypeptides
JP7492463B2 (ja) Ｆｇｆ－２１製剤
JP7600244B2 (ja) Ｆｇｆ－２１コンジュゲート製剤
US20240424072A1 (en) Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor
CA3252113A1 (en) Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210915

R150 Certificate of patent or registration of utility model

Ref document number: 6946304

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

LAPS Cancellation because of no payment of annual fees